[CAS NO. 186268-78-0] GPI-1485
PRODUCTS SPECIFICATIONS [186268-78-0]
DESCRIPTION [186268-78-0]
Overview
| MDL | MFCD02179274 |
|---|---|
| Molecular Weight | 241.28 |
| Molecular Formula | C12H19NO4 |
| SMILES | O=C(O)[C@H]1N(C(C(C(C)(C)CC)=O)=O)CCC1 |
Summary
GPI-1485 (GM1485), a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke [1] .
In Vitro
GPI-1485 (GM1485; 100 μM) induces cellular reprogramming and neural cell induction in normal human dermal fibroblasts (NHDF) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | Normal human dermal fibroblasts (NHDF) [1] |
| Concentration: | 100 μM |
| Incubation Time: | |
| Result: | Induced cellular reprogramming and neural cell induction. |
In Vivo
GPI-1485 (GM1485; 5 mg/kg; intraperitoneal injection; 6-week period of daily) improves long-term neurological recovery in rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Adult male Wistar rats, weighing 250-300 g [1] |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal injection; daily; for a total of 42 days |
| Result: | Administration improved neurological function and is consistent with an upregulation of endogenous neurogenesis following stroke in rats. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 414.46 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.1446 mL | 20.7228 mL | 41.4456 mL |
| 5 mM | 0.8289 mL | 4.1446 mL | 8.2891 mL |
| 10 mM | 0.4145 mL | 2.0723 mL | 4.1446 mL |
